{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:58:59Z","timestamp":1720677539907},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,22]]},"DOI":"10.7759\/cureus.56704","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T13:05:09Z","timestamp":1711112709000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Low-Dose Interleukin 2 Therapy in Conjunction With Standard Therapy in Patients With Systemic Lupus Erythematosus vs Rheumatoid Arthritis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Muhammad Faisal","family":"Riaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gourav","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotanna","family":"Umeano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaf","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah F","family":"Alhaddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian N","family":"Paulsingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang L","year":"2015","unstructured":"Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015, 278:369-95. 10.1111\/joim.12395","journal-title":"J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091462","article-title":"Pathophysiology and pathogenesis of immune-mediated inflammatory diseases: commonalities and differences","volume":"85","author":"Rahman P","year":"2010","unstructured":"Rahman P, Inman RD, El-Gabalawy H, Krause DO. Pathophysiology and pathogenesis of immune-mediated inflammatory diseases: commonalities and differences. J Rheumatol Suppl. 2010, 85:11-26. 10.3899\/jrheum.091462","journal-title":"J Rheumatol Suppl"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cden.2013.06.003","article-title":"Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management","volume":"57","author":"Fortuna G","year":"2013","unstructured":"Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013, 57:631-55. 10.1016\/j.cden.2013.06.003","journal-title":"Dent Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biom11070928","article-title":"Clinical and immunological biomarkers for systemic lupus erythematosus","volume":"11","author":"Yu H","year":"2021","unstructured":"Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021, 11:10.3390\/biom11070928","journal-title":"Biomolecules"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112857","article-title":"Management of rheumatoid arthritis: an overview","volume":"10","author":"Radu AF","year":"2021","unstructured":"Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021, 10:10.3390\/cells10112857","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102461","article-title":"The progress and prospect of regulatory T cells in autoimmune diseases","volume":"111","author":"Zhang X","year":"2020","unstructured":"Zhang X, Olsen N, Zheng SG. The progress and prospect of regulatory T cells in autoimmune diseases. J Autoimmun. 2020, 111:102461. 10.1016\/j.jaut.2020.102461","journal-title":"J Autoimmun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.04.003","article-title":"Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis","volume":"13","author":"Gonzalez-Rey E","year":"2007","unstructured":"Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med. 2007, 13:241-51. 10.1016\/j.molmed.2007.04.003","journal-title":"Trends Mol Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/08916931003782163","article-title":"Therapeutic potential of TGF-\u03b2-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases","volume":"44","author":"Zhou X","year":"2011","unstructured":"Zhou X, Kong N, Zou H, Brand D, Li X, Liu Z, Zheng SG. Therapeutic potential of TGF-\u03b2-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity. 2011, 44:43-50. 10.3109\/08916931003782163","journal-title":"Autoimmunity"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626193","article-title":"Function and role of regulatory T cells in rheumatoid arthritis","volume":"12","author":"Jiang Q","year":"2021","unstructured":"Jiang Q, Yang G, Liu Q, Wang S, Cui D. Function and role of regulatory T cells in rheumatoid arthritis. Front Immunol. 2021, 12:626193. 10.3389\/fimmu.2021.626193","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214024","article-title":"Tolerising cellular therapies: what is their promise for autoimmune disease?","volume":"78","author":"Mosanya CH","year":"2019","unstructured":"Mosanya CH, Isaacs JD. Tolerising cellular therapies: what is their promise for autoimmune disease?. Ann Rheum Dis. 2019, 78:297-310. 10.1136\/annrheumdis-2018-214024","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg M","year":"2015","unstructured":"Rosenzwajg M, Churlaud G, Mallone R, et al.. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015, 58:48-58. 10.1016\/j.jaut.2015.01.001","journal-title":"J Autoimmun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He J","year":"2016","unstructured":"He J, Zhang X, Wei Y, et al.. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016, 22:991-3. 10.1038\/nm.4148","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/2le8p4","article-title":"Cohort study of off-label use of low-dose IL-2 therapy for systemic autoimmune diseases","volume":"40","author":"Al Tabaa O","year":"2022","unstructured":"Al Tabaa O, Hamroun S, Leplay C, Fain O, Klatzmann D, Mekinian A. Cohort study of off-label use of low-dose IL-2 therapy for systemic autoimmune diseases. Clin Exp Rheumatol. 2022, 40:1809-10. 10.55563\/clinexprheumatol\/2le8p4","journal-title":"Clin Exp Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He J","year":"2020","unstructured":"He J, Zhang R, Shao M, et al.. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020, 79:141-9. 10.1136\/annrheumdis-2019-215396","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-019-0305-0","article-title":"Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients","volume":"20","author":"Zhao C","year":"2019","unstructured":"Zhao C, Chu Y, Liang Z, et al.. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients. BMC Immunol. 2019, 20:32. 10.1186\/s12865-019-0305-0","journal-title":"BMC Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2065145","article-title":"Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection","volume":"38","author":"Zhang JQ","year":"2022","unstructured":"Zhang JQ, Zhang SX, Wang J, et al.. Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection. Curr Med Res Opin. 2022, 38:1037-44. 10.1080\/03007995.2022.2065145","journal-title":"Curr Med Res Opin"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30018-9","article-title":"Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial","volume":"1","author":"Humrich JY","year":"2019","unstructured":"Humrich JY, von Spee-Mayer C, Siegert E, et al.. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 2019, 1:44-54. 10.1016\/S2665-9913(19)30018-9","journal-title":"Lancet Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00887-2","article-title":"Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"7","author":"Zhang X","year":"2022","unstructured":"Zhang X, Miao M, Zhang R, et al.. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2022, 7:67. 10.1038\/s41392-022-00887-2","journal-title":"Signal Transduct Target Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947341","article-title":"Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: a randomized controlled trial","volume":"13","author":"Wang J","year":"2022","unstructured":"Wang J, Zhang SX, Chang JS, et al.. Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: a randomized controlled trial. Front Immunol. 2022, 13:947341. 10.3389\/fimmu.2022.947341","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211011370","article-title":"Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis","volume":"13","author":"Zhang SX","year":"2021","unstructured":"Zhang SX, Wang J, Wang CH, et al.. Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2021, 13:1759720X211011370. 10.1177\/1759720X211011370","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200309000-00002","article-title":"Infectious complications in SLE after immunosuppressive therapies","volume":"15","author":"Kang I","year":"2003","unstructured":"Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003, 15:528-34. 10.1097\/00002281-200309000-00002","journal-title":"Curr Opin Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308101019","article-title":"Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality","volume":"18","author":"Goldblatt F","year":"2009","unstructured":"Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 2009, 18:682-9. 10.1177\/0961203308101019","journal-title":"Lupus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.04.030","article-title":"Impact of adverse events associated with medications in the treatment and prevention of rheumatoid arthritis","volume":"41","author":"Costello R","year":"2019","unstructured":"Costello R, David T, Jani M. Impact of adverse events associated with medications in the treatment and prevention of rheumatoid arthritis. Clin Ther. 2019, 41:1376-96. 10.1016\/j.clinthera.2019.04.030","journal-title":"Clin Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/228307-comparison-of-low-dose-interleukin-2-therapy-in-conjunction-with-standard-therapy-in-patients-with-systemic-lupus-erythematosus-vs-rheumatoid-arthritis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T13:05:13Z","timestamp":1711112713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/228307-comparison-of-low-dose-interleukin-2-therapy-in-conjunction-with-standard-therapy-in-patients-with-systemic-lupus-erythematosus-vs-rheumatoid-arthritis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.56704","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,22]]}}}